Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.17 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
3 Stocks Under $50 You Can Buy Hand Over Fist Right Now
A little up-front investment can go a long way with these three stocks. 
Via The Motley Fool
If You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today
The answer to that question will either make you wince or smile. 
Via The Motley Fool
The 3 Most Overlooked Stocks Set for a Triple-Digit Comeback
Learn how these overlooked stocks are set for a massive resurgence with leads in pharmaceutical, broadline retail and interactive media. 
Via InvestorPlace
Pfizer Inc. (NYSE: PFE) Near Top of Volume Charts in Wednesday Trading
Via Investor Brand Network
Exposures COVID-19
3 No-Brainer Stocks to Buy With $100 Right Now
A modest amount of money can go a long way in the stock market when it's put to work in time-tested businesses with well-defined competitive advantages. 
Via The Motley Fool
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost... 
Via Benzinga
A Closer Look at Pfizer's Options Market Dynamics
Via Benzinga
Is Pfizer Stock a Buy?
The pharmaceutical giant is laying the groundwork for its next heyday. 
Via The Motley Fool
Pneumococcal Pneumonia Vaccination Can Save Your Life
Via StatePoint Media
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
Want $1,000 in Annual Dividend Income? Invest $13,200 in These Ultra-High-Yield Dividend Stocks.
The average yield from these stocks is more than five times the market average. 
Via The Motley Fool
The Smartest Dividend Stocks to Buy With $400 Right Now
These three stocks are bargains with great dividends. 
Via The Motley Fool
QFunction: Cybersecurity Company Announces Launch of Customized AI Solutions
Via Press Release Distribution Service
Topics Artificial Intelligence
Exposures Artificial Intelligence
Where Will Pfizer Stock Be in 10 Years?
Is this top healthcare stock a good buy for the long run? 
Via The Motley Fool
Decoding Pfizer's Options Activity: What's the Big Picture?
Via Benzinga
2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever
These dividend payers have a long history of steady dividend payout raises, and they both offer yields above 6% at recent prices. 
Via The Motley Fool
Is Pfizer Stock the Biggest Bargain in the S&P 500?
When something seems too good to be true it might not be. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
Capitalize on the biotech sector's boom with these three top biotech stocks to buy, driven by aging demographics and advanced treatments. 
Via InvestorPlace
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
From Pfizer Inc.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Current Analysis: Pfizer (PFE)
Pfizer (PFE) is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Over the past year, Pfizer’s share price fell 36.6% from $41.50 to $26.31 as of Wednesday’s... 
Via Talk Markets
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... 
Via Benzinga
7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape
Although the market may be grumbling over certain issues, concerned investors can trust these healthcare stocks to deliver the goods. 
Via InvestorPlace
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
PM Fumio Kishida Urges US Tech Giants To Invest In Japan: 'I'm Strongly Promoting Policies Toward The Next Economic Stage'
During a roundtable in Washington, Kishida highlighted the importance of U.S. investments in Japan, particularly in emerging technologies like semiconductors, AI, and quantum computing. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around. 
Via InvestorPlace
Pfizer Seeks Expanded Use Of Abrysvo As Vaccine Shows Potential In 18+ Patients
Discover pivotal Phase 3 trial results for Pfizer's Abrysvo vaccine in adults 18-59 at risk of severe RSV disease. Achieved immunogenicity and safety milestones pave the way for potential regulatory... 
Via Benzinga
How's AT&T Handling Things?
We've also got a look at 3M's spinoff, gold prices, and the beef industry. 
Via The Motley Fool
2 Ultra-High-Yield Dividend Stocks to Buy and Hold Forever
A rate cut would likely be a boon for these two ultra-high yield dividend stocks. 
Via The Motley Fool
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
From Pfizer Inc.
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.